Skip to main content

Evolving Treatment Strategies in Pediatric Leukemia

June 12, 2024

Recording will be available soon.


Target Audience

This activity is intended for pediatric hematologist/oncologists, oncology nurses, social workers, and other healthcare professionals involved in the care of pediatric patients with hematologic malignancies.

Course content level for social workers: all levels

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe common childhood blood cancers, including ALL and AML 
  • Identify signs and symptoms of childhood blood cancers and diagnostic tests 
  • Explain treatments, including the role of clinical trials, and LLS PedAL, a precision medicine clinical trial for pediatric acute leukemia 
  • Describe strategies for management of short- and long-term side effects of treatment 
  • Explain the importance of following a care plan, including long-term follow-up and communication between the pediatrician/family physician and the pediatric oncologist   
  • Describe psychosocial concerns related to patients with pediatric cancer  


Branko Cuglievan, MD
Assistant Professor, Pediatrics - Patient Care
Section Chief, Leukemia/Lymphoma
Children's Cancer Hospital
The University of Texas MD Anderson Cancer Center
Houston, TX

Romeo Torres, MSN, APRN, FNP-BC, CPHON 
Pediatric Leukemia/Lymphoma 
MD Anderson Cancer Center
Houston, TX

Continuing Education Information

Physician Continuing Medical Education

Jointly Accredited Provider

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The Leukemia & Lymphoma Society.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this CME activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Registered Nursing Credit Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.

Interprofessional Continuing Education

Interprofessional Continuing Education (IPCE) credit

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.

Continuing Physician Assistant Education

AAPA logo

Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Social Worker Continuing Education
The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved as an ACE provider to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Regulatory boards are the final authority on courses accepted for continuing education credit. ACE provider approval period: 12/10/2023-12/10/2026. Social workers completing this course receive 1.0 clinical continuing education credit.

The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0117. LLS maintains responsibility for the program. Social workers will receive 1.0 clinical CE contact hour for this activity.

There are no fees for participating in or receiving credit for this activity.

This activity is jointly provided by The Leukemia & Lymphoma Society and Postgraduate Institute for Medicine.

There is no commercial support associated with this CE activity.

For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at